Tuesday 23rd February 2016 |
Text too small? |
New Zealand life science and medical research companies will be able to bid for millions of Australian dollars in funding to support new drugs and medical developments after the government signed up to Australia's Medical Research Commercialisation Fund.
New Zealand will pay A$500,000 a year to be part of the fund, the same amount paid by Australian states, Science and Innovation Minister Steven Joyce said in a statement. The fund was set up in 2007 and other investors include Australian Superannuation funds. It is operated by Brandon Capital Partners.
Companies compete for investment and support for the pre-clinical development and commercialisation of discoveries. Early funding can receive up to A$3 million, with the potential for a further A$17 million in investment.
Joyce said the deal was vital in attracting high quality business investment to New Zealand: "Since 2007, the MRCF has supported the development of 24 start-up companies, with some notable successes, such as Spinifex Pharmaceuticals, which sold this year for over US$700 million, and Fibrotech Therapeutics, which netted US$557 million in 2014.”
Ideas and developments are chosen on whether they represent significant breakthroughs, the size and scale of potential markets and the strength of the intellectual property.
BusinessDesk.co.nz
No comments yet
Contact secures gas supply
MCK - MARKET UPDATE ON RESPONSE TO CDLHHNZ TAKEOVER NOTICE
January 22nd Morning Report
ATM - 1H25 Results Announcement Date and Webcast Notification
MCK RECEIVES TAKEOVER OFFER FROM CDLHHNZ
PHL - Senior Manager Change
Steel & Tube 1H25 Interim Results to be announced on 24 Feb
January 20th Morning Report
KPG - Changes to the Kiwi Property Board
IKE - Timing of Quarterly Performance Update and Conference Call